Teva stock: At USD 41.29, Teva stock sits 1.74 percent below its 52-week high
Published on 10/19/2026 at 17:07 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSPrice position and upcoming results
- Teva stock stood 1.74 percent below its 52-week high on October 19, 2026.
- Revenue reached USD 4.14 billion in the second quarter ended June 30, 2026.
- Teva stock costs USD 41.29 at 11:04 a.m. ET on October 19, 2026, down 0.51 percent on the NYSE versus the prior close of October 16, 2026.
- Teva traded at a P/E ratio of 69.45 on October 19, 2026.
Teva Pharmaceutical Industries will release its third-quarter 2026 results on November 3, 2026, at 7:00 a.m. ET, according to Teva. Teva was trading at USD 41.29 on October 19, 2026 at 11:04 a.m. ET, down 0.51 percent on the NYSE versus the prior close of October 16, 2026 at USD 41.50.
Second-quarter revenue reached USD 4.14 billion
Teva reported revenue of USD 4.14 billion for the second quarter ended June 30, 2026, according to MarketBeat. The quarter also carried a net loss of USD 576.00 million and diluted earnings per share of minus USD 0.49, giving investors two different signals from the same reporting period.
Teva stock sits near its yearly high
The NYSE price of USD 41.29 was USD 0.73 below Teva's 52-week high of USD 42.02 on October 19, 2026, a distance of 1.74 percent. The 52-week low was USD 18.83. The session range ran from USD 41.27 to USD 41.87, while volume reached 713,472 shares against an average of 5,721,756 shares.
Valuation meets a November date
Teva's market capitalization stood at USD 48.1 billion on October 19, 2026, and its P/E ratio was 69.45. Those figures place the stock close to its yearly high while the next reporting date approaches. The company is scheduled to publish third-quarter results on November 3, 2026, followed by an 8:00 a.m. ET conference call, as stated by Teva.
Comparison with peers
TEVA (NYSE, USD): minus 0.51 percent, P/E 69.45, market capitalization USD 48.1 billion
Bristol-Myers Squibb (NYSE, USD): minus 1.24 percent, P/E 12.98, market capitalization USD 120.5 billion
Amgen (NASDAQ, USD): minus 0.83 percent, P/E 26.65, market capitalization USD 231.9 billion
Price position remains the key signal
Teva's 1.74 percent distance from its 52-week high is the clearest technical marker in the current quote. The next earnings release on November 3 will provide the next scheduled test of revenue, earnings and pipeline expectations.
The further course of trading is shown by the continuously updated real-time quote of Teva stock.
Teva stock facts
- Company: Teva Pharmaceutical Industries Limited
- ISIN: US8816242098
- Ticker: TEVA
- Primary exchange: NYSE
- Price NYSE (as of October 19, 2026, 11:04 a.m. ET): USD 41.29
- Change versus prior close: minus 0.51 percent
- Market capitalization: USD 48.1 billion (as of October 19, 2026)
- 52-week range: USD 18.83-42.02 (as of October 19, 2026)
- Sector / Industry: Healthcare / Drug Manufacturers - Specialty and Generic
- Next earnings date: November 3, 2026
Market context: Market report S&P 500.
